Drugs / Remdesivir
Remdesivir
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | VEKLURY | — | 2022-01-21 – 2024-02-28 | fda.gov ↗ |
| Approved | US (FDA) | VEKLURY | — | 2020-10-22 | fda.gov ↗ |
| Approved | EU (EMA) | Veklury | — | 2020-07-03 | europa.eu ↗ |
Trials 48 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04560231 | Jun → Nov 2020 | Orthocoronavirinae infectious disease | Lahore General Hospital | Unknown | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT04480333 | Sep → Dec 2020 | COVID-19, neurodegenerative disease, neuronitis, pneumonia +1 | Biomed Industries, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT05925140 | Mar 2020 → Dec 2024 | COVID-19 | Lebanese University | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04539262 | Sep 2020 → Feb 2021 | COVID-19 | Gilead Sciences | Completed | No outcome recorded |
| Phase 1/2 | NCT04746183 | Jul 2020 → Mar 2027 expected | COVID-19 | University of Liverpool | Recruiting | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT06551844 | Apr 2026 → Dec 2029 expected | dengue disease, interferon antiviral depressor | Oxford University Clinical Research Unit, Vietnam | Recruiting | No outcome recorded |
| Phase 2 | NCT06817889 | Dec 2025 → Nov 2027 expected | autoimmune disease, hematopoietic and lymphoid system neoplasm, respiratory syncytial virus infectious disease | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07197164 | Sep 2025 → Dec 2026 expected | COVID-19 | Fight AIDS and Infectious Diseases Foundation | Recruiting | No outcome recorded |
| Phase 2 | NCT06873633 | Jul 2025 → Jun 2026 overdue | respiratory syncytial virus infectious disease | PENTA Foundation | Recruiting | No outcome recorded |
| Phase 2 | NCT05587894 | Apr 2023 → Jun 2026 overdue | COVID-19, immunodeficiency disease | ANRS, Emerging Infectious Diseases | Recruiting | No outcome recorded |
| Phase 2 | NCT05041907 | Sep 2021 → Jan 2027 expected | COVID-19 | University of Oxford | Recruiting | No outcome recorded |
| Phase 2 | NCT04385719 | May → Jul 2021 | Ebola hemorrhagic fever, HIV infectious disease | Makerere University | Completed | No outcome recorded |
| Phase 2 | NCT05184127 | Apr → Sep 2021 | COVID-19 | National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia | Completed | No outcome recorded |
| Phase 2 | NCT04596839 | Sep 2020 → Apr 2021 | COVID-19 | Dr. Md. Alimur Reza | Completed | No outcome recorded |
| Phase 2 | NCT04321993 | Apr 2020 → Apr 2024 | COVID-19 | Lisa Barrett | Unknown | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT04431453 | Jul 2020 → Feb 2023 | COVID-19 | Gilead Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT04575064 | Jun 2020 → Mar 2022 | COVID-19 | Professor Dr. Bernd Mühlbauer | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT04345419 | Jun → Dec 2020 | COVID-19 | Tanta University | Completed | No outcome recorded |
| Phase 2/3 | NCT04351724 | Apr 2020 → Dec 2021 | COVID-19 | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 2/3 | NCT04349410 | Apr → Sep 2020 | COVID-19 | The Camelot Foundation | Completed | No outcome recorded |
| Phase 2/3 | NCT03719586 | Nov 2018 → Sep 2019 | Ebola hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 318 trials | ||||||
| Phase 3 | NCT07013474 | Jul 2025 → Sep 2027 expected | COVID-19 | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT04843761 | Apr 2021 → Aug 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT06729593 | Apr 2021 → Aug 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT04832880 | Apr 2021 → Mar 2022 | COVID-19 | ASST Fatebenefratelli Sacco | Unknown | No outcome recorded |
| Phase 3 | NCT04745351 | Mar 2021 → Apr 2022 | COVID-19 | Gilead Sciences | Terminated | No outcome recorded |
| Phase 3 | NCT04610541 | Oct 2020 → Oct 2021 | COVID-19 | University of Pecs | Unknown | No outcome recorded |
| Phase 3 | NCT04501952 | Sep 2020 → May 2021 | COVID-19 | Gilead Sciences | Terminated | No outcome recorded |
| Phase 3 | NCT04693026 | Sep 2020 → Feb 2021 | COVID-19, acute respiratory distress syndrome | M Abdur Rahim Medical College and Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04678739 | Aug 2020 → Jan 2021 | COVID-19, acute respiratory distress syndrome | M Abdur Rahim Medical College and Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04483960 | Jul 2020 → Jul 2025 | COVID-19 | University of Melbourne | Unknown | No outcome recorded |
| Phase 3 | NCT04853901 | Jul 2020 → Jan 2021 | COVID-19 | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT04315948 | Mar 2020 → Jul 2022 | COVID-19 | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 3 | NCT04292730 | Mar → Apr 2020 | COVID-19 | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT04292899 | Mar → Apr 2020 | COVID-19 | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT04280705 | Feb → May 2020 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT04252664 | Feb → Apr 2020 | COVID-19 | Capital Medical University | Suspended | No outcome recorded |
| Phase 3 | NCT04257656 | Feb → Mar 2020 | COVID-19 | Capital Medical University | Terminated | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT06792214 | Jan 2025 → Jan 2026 overdue | long COVID-19 | Mount Sinai Hospital, Canada | Recruiting | No outcome recorded |
| Phase 4 | NCT05911906 | Oct 2024 → Sep 2025 | COVID-19 | University of Derby | Completed | No outcome recorded |
| Phase 4 | NCT05502081 | Sep → Dec 2022 | COVID-19 | Mansoura University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04978259 | Jul 2021 → Feb 2023 | COVID-19 | Clinical Urology and Epidemiology Working Group | Unknown | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06610643 | Sep 2024 → Sep 2026 expected | COVID-19, immunodeficiency disease | National Taiwan University Hospital | Not yet recruiting | No outcome recorded |
| — | NCT05024006 | Apr 2020 → Apr 2021 | COVID-19 | University of the Philippines | Completed | No outcome recorded |
| — | NCT04492501 | Apr → Jul 2020 | COVID-19, acute respiratory distress syndrome, cytokine release syndrome | UNICEF | Completed | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT04323761 | — | COVID-19 | Gilead Sciences | Approved for marketing | No outcome recorded |
| — | NCT04302766 | — | COVID-19 | U.S. Army Medical Research and Development Command | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 39 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06860282 Comparator | Dec 2022 → Mar 2023 | COVID-19, viral pneumonia | Heronova Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04790240 Comparator | Jan 2025 → Dec 2026 expected | COVID-19 | All Natural Medicine Clinic, LLC | Recruiting | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT04988035 Background | Aug 2021 → Apr 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT04391309 Background | Apr 2021 → Feb 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT04647695 Comparator | Nov 2020 → Jul 2021 | COVID-19 | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 2 | NCT04583969 Background | Oct 2020 → Apr 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT04583956 Background | Oct 2020 → Sep 2021 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT04488081 Background | Jul 2020 → Jul 2028 expected | COVID-19 | QuantumLeap Healthcare Collaborative | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04410354 Comparator | Jun → Dec 2020 | COVID-19 | ViralClear Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02818582 Comparator | Jul 2016 → Aug 2020 | Ebola hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04395170 Background | Sep → Dec 2020 | COVID-19 | Lifefactors Zona Franca, SAS | Unknown | No outcome recorded |
| Phase 2/3 | NCT04321616 Comparator | Mar → Aug 2020 | COVID-19, adult acute respiratory distress syndrome | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 322 trials | ||||||
| Phase 3 | NCT05271929 Background | Apr 2022 → Jan 2024 | COVID-19 | German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen | Terminated | No outcome recorded |
| Phase 3 | NCT05780541 Background | Sep 2021 → Apr 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 3 | NCT05185284 Comparator | Aug → Dec 2021 | COVID-19 | Promomed, LLC | Completed | No outcome recorded |
| Phase 3 | NCT04970719 Background | Jul → Dec 2021 | pneumonia | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | Withdrawn | No outcome recorded |
| Phase 3 | NCT05780463 Background | Jun 2021 → Feb 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT04784559 Comparator | Jun 2021 → Mar 2023 | COVID-19 | PharmaMar | Terminated | No outcome recorded |
| Phase 3 | NCT04647669 Comparator | Jun → Nov 2021 | COVID-19 | The University of The West Indies | Unknown | No outcome recorded |
| Phase 3 | NCT05780437 Background | Feb 2021 → Jan 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT04713176 Background | Feb 2021 → May 2022 | COVID-19 | Daewoong Pharmaceutical Co. LTD. | Terminated | No outcome recorded |
| Phase 3 | NCT04694612 Comparator | Jan → Mar 2021 | COVID-19 | Nepal Health Research Council | Unknown | No outcome recorded |
| Phase 3 | NCT04675086 Background | Jan → Sep 2021 | COVID-19, viral pneumonia | Blessing Corporate Services, Inc | Withdrawn | No outcome recorded |
| Phase 3 | NCT05780424 Background | Dec 2020 → Jun 2021 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT05780281 Background | Dec 2020 → Jun 2021 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT04640168 Background | Dec 2020 → May 2021 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT04593940 Comparator | Oct 2020 → Jan 2022 | COVID-19 | Daniel Benjamin | Completed | No outcome recorded |
| Phase 3 | NCT04546581 Background | Oct 2020 → May 2021 | COVID-19, severe acute respiratory syndrome | University of Minnesota | Completed | No outcome recorded |
| Phase 3 | NCT05780268 Background | Aug 2020 → Feb 2021 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT04492475 Background | Aug → Dec 2020 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT04501978 Background | Aug 2020 → Apr 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT04409262 Background | Jun 2020 → Feb 2021 | pneumonia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT04401579 Background | May → Jul 2020 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT04351152 Background | May 2020 → Mar 2021 | COVID-19 | Humanigen, Inc. | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT04738045 Comparator | Nov 2020 → Mar 2021 | COVID-19 | Ahmed Essam | Unknown | No outcome recorded |
| Phase 4 | NCT04779047 Comparator | Oct 2020 → Mar 2021 | COVID-19, pneumonia | October 6 University | Unknown | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT04865237 Background | Mar 2021 → Jul 2022 | COVID-19 | Imperial College London | Completed | No outcome recorded |
| — | NCT04980534 Background | Jan → Jun 2021 | COVID-19, pneumonia | Catalysis SL | Completed | No outcome recorded |
| — | NCT04871633 Comparator | Aug → Nov 2020 | COVID-19 | King Edward Medical University | Completed | No outcome recorded |
Press releases naming this drug 41 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-12 | Gilead Sciences | Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief gilead.com ↗ |
| 2024-03-05 | Gilead Sciences | New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19 gilead.com ↗ |
| 2023-09-19 | Gilead Sciences | CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment gilead.com ↗ |
| 2023-08-24 | Gilead Sciences | FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment gilead.com ↗ |
| 2023-07-14 | Gilead Sciences | FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis gilead.com ↗ |
| 2023-05-26 | Gilead Sciences | CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis gilead.com ↗ |
| 2023-04-16 | Gilead Sciences | Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations gilead.com ↗ |
| 2023-02-21 | Gilead Sciences | Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients gilead.com ↗ |
| 2022-09-16 | Gilead Sciences | CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19 gilead.com ↗ |
| 2022-09-15 | Gilead Sciences | WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline gilead.com ↗ |
| 2022-07-22 | Gilead Sciences | CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19 gilead.com ↗ |
| 2022-07-19 | Gilead Sciences | Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir) gilead.com ↗ |
| 2022-04-25 | Gilead Sciences | Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19 gilead.com ↗ |
| 2022-04-24 | Gilead Sciences | Several New Studies Presented at ECCMID 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19 gilead.com ↗ |
| 2022-02-11 | Gilead Sciences | Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies gilead.com ↗ |
| 2022-02-11 | Gilead Sciences | Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022 gilead.com ↗ |
| 2022-01-21 | Gilead Sciences | FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression gilead.com ↗ |
| 2021-12-22 | Gilead Sciences | Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19 gilead.com ↗ |
| 2021-12-21 | Gilead Sciences | European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression gilead.com ↗ |
| 2021-10-19 | Gilead Sciences | Gilead Sciences Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia gilead.com ↗ |
| 2021-09-22 | Gilead Sciences | Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19 gilead.com ↗ |
| 2021-06-21 | Gilead Sciences | Gilead’s Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets gilead.com ↗ |
| 2021-04-26 | Gilead Sciences | Gilead Sciences Announces Steps to Expand Availability of Remdesivir in India gilead.com ↗ |
| 2021-03-11 | Roche Global Development | Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia roche.com ↗ |
| 2020-10-22 | Gilead Sciences | U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19 gilead.com ↗ |
| 2020-10-08 | Gilead Sciences | Gilead Sciences Signs Joint Procurement Agreement With the European Commission for Veklury® (remdesivir) gilead.com ↗ |
| 2020-10-08 | Gilead Sciences | Final Results of National Institute of Allergy and Infectious Diseases’ ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19 gilead.com ↗ |
| 2020-10-01 | Gilead Sciences | Gilead Sciences Update on Supply and Distribution of Veklury® (remdesivir) in the United States gilead.com ↗ |
| 2020-08-28 | Gilead Sciences | Gilead’s Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19 gilead.com ↗ |
| 2020-08-10 | Gilead Sciences | Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury® (Remdesivir) for the Treatment of COVID-19 gilead.com ↗ |
| 2020-08-07 | Pfizer | Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19 pfizer.com ↗ |
| 2020-07-10 | Gilead Sciences | Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19 gilead.com ↗ |
| 2020-07-03 | Gilead Sciences | European Commission Grants Conditional Marketing Authorization for Gilead’s Veklury® (remdesivir) for the Treatment of COVID-19 gilead.com ↗ |
| 2020-06-01 | Gilead Sciences | Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19 gilead.com ↗ |
| 2020-05-07 | Gilead Sciences | Gilead Announces Approval of Veklury® (remdesivir) in Japan for Patients With Severe COVID-19 gilead.com ↗ |
| 2020-05-01 | Gilead Sciences | Gilead’s Investigational Antiviral Remdesivir Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of COVID-19 gilead.com ↗ |
| 2020-04-29 | Gilead Sciences | Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases’ Study of Investigational Antiviral Remdesivir for COVID-19 gilead.com ↗ |
| 2020-04-29 | Gilead Sciences | Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19 gilead.com ↗ |
| 2020-04-10 | Gilead Sciences | Data on 53 Patients Treated With Investigational Antiviral Remdesivir Through the Compassionate Use Program Published in New England Journal of Medicine gilead.com ↗ |
| 2020-02-26 | Gilead Sciences | Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19 gilead.com ↗ |
| 2015-10-21 | Gilead Sciences | Gilead Provides Update on Investigational Compound, GS-5734, for the Treatment of Ebola Virus Disease gilead.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 91 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | remdesivir | “Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who...” NCT05587894 ↗86“Participants were randomized 1:1 to receive intravenous remdesivir (GS-5734; Gilead Sciences) or matching placebo administered once daily by intravenous infusion over 1 hour on...” PMID 33709142 ↗ Nov 2021 “standard therapy which included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.” NCT05184127 ↗ “Standard of care therapy can include remdesivir and/or dexamethasone per institutional treatment guidelines or written policies” NCT04351152 ↗ “remdesivir (Veklury), Colchicine, anti-SARS-CoV-2 monoclonal antibodies, bamlanivimab, Casirivimab \& Imdevimab.” NCT04790240 ↗ “To date, these therapies may include remdesivir, chloroquine, hydroxychloroquine, azithromycin.” NCT04395170 ↗ “Remdesivir IV 200 mg for the first day and then 100 mg daily for the next 4 days” NCT04980534 ↗ “Remdesivir inhibits the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp; Nsp12).” PMID 39699245 ↗ Dec 2024 “A combination of 5-day remdesivir and 10-day Nirmatrelvir/Ritonavir” NCT06610643 ↗ “GS-5734 (Remdesivir) is an antiviral drug” NCT04480333 ↗ “The Antiviral treatment is Remdesivir.” NCT04675086 ↗ “Remdesivir” NCT05271929 ↗ |
| Known as | GS-443902 | “Remdesivir (GS-443902) is a nucleoside analogue - RNA dependent RNA polymerase inhibitor.” NCT06551844 ↗ |
| Known as | GS-5734 | “Remdesivir (GS-5734), a nucleoside analogue prodrug” PMID 32423584 ↗ Apr 2020 |
| Known as | RDV | “Remdesivir (RDV,GS-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus families including Filoviridae,...” NCT04302766 ↗5“The primary objective of this study is to characterize the impact of inhaled remdesivir (RDV) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in...” NCT04539262 ↗ “Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)” NCT04323761 ↗ “Remdesivir (RDV)” NCT05925140 ↗ “Remdesivir (RDV)” NCT07197164 ↗ “Remdesivir (RDV)” NCT04501952 ↗ |
| Known as | Veklury | “Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who...” NCT05587894 ↗1“remdesivir (Veklury)” NCT04790240 ↗ |
| Action | Inhibit | “Remdesivir is an antiviral medicine with properties to inhibit viral replication of SARS-CoV-2.” PMID 34350582 ↗ Aug 2021 |
| Modality | Small molecule | “Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human coronaviruses” PMID 32423584 ↗ Apr 2020 |
| Route | Intravenous | “Daily GS-5734 delivered intravenously (IV) for 5 days” NCT02818582 ↗ |